These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8149526)

  • 21. Luminal loss and restenosis after coronary angioplasty. The role of lipoproteins and lipids.
    Jorgensen B; Simonsen S; Endresen K; Forfang K; Egeland T; Høstmark AT; Thaulow E
    Eur Heart J; 1999 Oct; 20(19):1407-14. PubMed ID: 10487801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of lipoprotein(a) concentration and apo(a) isoform size with restenosis after percutaneous transluminal coronary angioplasty.
    Sirikci O; Aytekin V; Demiroglu IC; Demiroglu C; Marcovina SM
    Int J Clin Lab Res; 2000; 30(2):93-9. PubMed ID: 11043503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Preventive effect of pravastatin on restenosis following coronary angioplasty: prospective randomized trial].
    Iwasaki K; Kusachi S; Hina K; Yamasaki S; Nishiyama O; Takaishi A; Kita T; Taniguchi G
    J Cardiol; 1995 Jan; 25(1):15-21. PubMed ID: 7877098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for restenosis after percutaneous transluminal coronary angioplasty: role of lipoprotein (a).
    Yamamoto H; Imazu M; Yamabe T; Ueda H; Hattori Y; Yamakido M
    Am Heart J; 1995 Dec; 130(6):1168-73. PubMed ID: 7484765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Restenosis rate after multiple percutaneous transluminal coronary angioplasty procedures at the same site. A quantitative angiographic study in consecutive patients undergoing a third angioplasty procedure for a second restenosis.
    Bauters C; Mc Fadden EP; Lablanche JM; Quandalle P; Bertrand ME
    Circulation; 1993 Sep; 88(3):969-74. PubMed ID: 8353924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty.
    Chiarugi L; Prisco D; Antonucci E; Capanni M; Fedi S; Liotta AA; Margheri M; Simonetti I; Gensini GF; Abbate R
    Atherosclerosis; 2001 Jan; 154(1):129-35. PubMed ID: 11137091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of enhanced insulin secretion during an oral glucose tolerance test as a predictor of restenosis after direct percutaneous transluminal coronary angioplasty during acute myocardial infarction in patients without diabetes mellitus.
    Osanai H; Kanayama H; Miyazaki Y; Fukushima A; Shinoda M; Ito T
    Am J Cardiol; 1998 Mar; 81(6):698-701. PubMed ID: 9527077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apolipoprotein epsilon 4 homozygosity--a determinant of restenosis after coronary angioplasty.
    van Bockxmeer FM; Mamotte CD; Gibbons FR; Taylor RR
    Atherosclerosis; 1994 Oct; 110(2):195-202. PubMed ID: 7848369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of restenosis by bezafibrate after successful coronary angioplasty.
    Ishiwata S; Nakanishi S; Nishiyama S; Seki A
    Coron Artery Dis; 1995 Nov; 6(11):883-9. PubMed ID: 8696533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term and long-term effects of low-density lipoprotein (LDL) apheresis on restenosis after percutaneous transluminal coronary angioplasty (PTCA): is lowering Lp(a) by LDL apheresis effective on restenosis after PTCA?
    Kanemitsu S; Takekoshi N; Matsui S; Tsugawa H; Ohkubo S; Kitayama M; Matsuda T; Senma J; Masuyama K; Yamagata T; Murakami E
    Ther Apher; 1998 Feb; 2(1):65-70. PubMed ID: 10227791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA).
    DeMaio SJ; King SB; Lembo NJ; Roubin GS; Hearn JA; Bhagavan HN; Sgoutas DS
    J Am Coll Nutr; 1992 Feb; 11(1):68-73. PubMed ID: 1541798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Normalization of lipid metabolism disturbances and clinical course after percutaneous coronary angioplasty: 6 month observation].
    Ochała A; Gabrylewicz B; Bartnik M; Garbocz P; Wycisk A; Lewicki A; Kaźmierski M; Tendera M
    Pol Arch Med Wewn; 2000 Dec; 104(6):833-41. PubMed ID: 11424662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L-ART).
    Yamaguchi H; Lee YJ; Daida H; Yokoi H; Miyano H; Kanoh T; Ishiwata S; Kato K; Nishikawa H; Takatsu F
    Chem Phys Lipids; 1994 Jan; 67-68():399-403. PubMed ID: 8187240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of relationship between plasma Lp(a), Lp-AI, anti-oxidized LDL autoantibodies, LDL immune complexes concentrations and restenosis after percutaneous transluminal coronary angioplasty.
    Boullier A; Walters-Laporte E; Hamon M; Tailleux A; Amant C; Amouyel P; Fruchart J; Bertrand M; Duriez P
    Clin Chim Acta; 2000 Sep; 299(1-2):129-40. PubMed ID: 10900299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of serum lipid concentrations on restenosis after successful de novo percutaneous transluminal coronary angioplasty in patients with total cholesterol 160 to 240 mg/dl and triglycerides < 350 mg/dl.
    Dzavik V; Teo KK; Yokoyama S; Modi R; Dinwoodie A; Burton JR; Tymchak WJ; Montague TJ
    Am J Cardiol; 1995 May; 75(14):936-8. PubMed ID: 7733005
    [No Abstract]   [Full Text] [Related]  

  • 36. [Identification of predictive factors associated with recurrent restenosis after second percutaneous transluminal coronary angioplasty].
    Kishi K; Hiasa Y; Tanaka H; Kinoshita M; Tanimoto M; Wada T; Aihara T
    J Cardiol; 1997 Jan; 29(1):7-12. PubMed ID: 9023674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
    Tsuchikane E; Fukuhara A; Kobayashi T; Kirino M; Yamasaki K; Kobayashi T; Izumi M; Otsuji S; Tateyama H; Sakurai M; Awata N
    Circulation; 1999 Jul; 100(1):21-6. PubMed ID: 10393676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty--a report from the M-HEART Group.
    Macdonald RG; Henderson MA; Hirshfeld JW; Goldberg SH; Bass T; Vetrovec G; Cowley M; Taussig A; Whitworth H; Margolis JR
    Am J Cardiol; 1990 Oct; 66(12):926-31. PubMed ID: 2220614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological risk factors for restenosis after percutaneous transluminal coronary angioplasty.
    Benchimol D; Bonnet J; Benchimol H; Drouillet F; Duplaa C; Couffinhal T; Desgranges C; Bricaud H
    Int J Cardiol; 1993 Jan; 38(1):7-18. PubMed ID: 8444504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.